Don Pinkel has a tremendous record of accomplishment in the development of modern therapies for childhood acute lymphoblastic leukemia (ALL). He had a pivotal role in the development and evolution of early 'Total Therapy' studies for childhood ALL at St Jude Children's Research Hospital in the 1960s and 1970s. He dared to believe that this, until then, universally fatal disease could be cured and saw his dreams come true. At about the same time, others, most notably Don Thomas, dared to believe that allogeneic hematopoietic stem cell transplantation (HSCT) could cure patients with leukemia. Time has shown that both Don Pinkel and Don Thomas were correct. Today, over 80% of children diagnosed with ALL in North America and Western Europe will be cured, and HSCT has cured thousands of children and adults with leukemia, bone marrow failure states and other disorders. Given this background, we are troubled by the recent editorial by Dr Pinkel updating his view that the use of allogeneic HSCT to treat children with leukemia is 'a practice whose time has gone'. 1 Although we wish that all children with leukemia could be cured with chemotherapy and therefore have no need for HSCT, this is simply not the case today, and is unlikely to become true in the near future. As specialists in the treatment of childhood leukemia, with or without HSCT, we believe, our job is to carefully weigh the relative advantages and disadvantages of chemotherapy or HSCT approaches in different clinical settings, develop rational treatment algorithms and design clinical trials to answer critical questions. We believe that the editorial by Dr Pinkel fails to put these different treatment modalities in the proper perspective and are particularly concerned that his portrayal of HSCT as curing children at the cost of universal, significant late effects, while late effects of chemotherapy approaches are not mentioned, paints an inaccurate picture. Similarly, we are concerned that studies showing advantages in survival with HSCT in certain disease states were brushed aside by speculation of bias.
SCT is in some ways an easy target. It is a complicated treatment modality that is advancing and changing rapidly, requiring focused attention to maintain a contemporary knowledge base from which medical advice can appropriately be made. Reliance on outdated studies risks invalid assumptions. A simple fact must be remembered in this discussion: the approach works. It is a well-established, ethical, nonexperimental therapy for children that cures leukemia. Major progress has been made over the past two decades in human leukocyte antigen (HLA) typing, stem cell source choices, graft vs host disease prevention, transplant-related mortality and cure rates after unrelated donor transplantation. 2 The large majority of children who undergo HSCT live happy, productive lives, with good health, and normal growth and development.
A better approach is an ongoing, rigorous assessment of the changing field leukemia therapy, making judicious, and as much as possible, data-driven choices of when to give more or less intense therapy. This includes a careful judgment of when the risk of relapse is high enough to justify the use of allogeneic HSCT, and for what disease states there is solid empirical evidence that HSCT provides a survival advantage in comparison with other treatment approaches. We agree with several points that Dr Pinkel made: reasonable comparative studies have shown that most infants with ALL do not benefit from HSCT in complete remission 1 (CR1); evidence is emerging that most patients with Ph þ ALL may also no longer require CR1 HSCT (assuming long-term data from the Children's Oncology Group AALL0031 trial 3 continue to show prolonged disease free survival; and children with better-risk acute myeloid leukemia do not require HSCT from matched siblings in CR1. However, there are children who benefit from transplant (Table 1) . A more detailed review of our recommendations concerning the role of transplantation for children with ALL and acute myeloid leukemia is in preparation, but several points made in the editorial by Dr Pinkel need to be addressed quickly. In addition, we will outline a few principles that should be considered when evaluating studies that attempt to compare chemotherapy and HSCT outcomes.
We struggle with Dr Pinkel's claim that use of allogeneic HSCT is not justified because it deprives children of the goal of Table 1 Current COG indications for allogeneic HSCT in pediatric ALL and AML Letters to the Editor all cancer therapy: 'normal health with normal capacity for growth and development.' He lists the offenses of HSCT including chronic graft vs host disease, multiple endocrine disorders, second cancers, sterility, renal insufficiency, obstructive and restrictive pulmonary disease, aseptic necrosis of bone and leukoencephalopathy. Yes, some children treated with HSCT die of treatment complications and others have major long-term side effects. Unfortunately, the same is true for chemotherapy treatments, particularly those used for treatment of high-risk subsets such as infants with ALL, or children and adolescents with relapsed/refractory ALL and acute myeloid leukemia. Many of the adverse effects associated with both treatment modalities occur because of previous therapy. Studies that simply catalog late effects after HSCT do not help address comparison of approaches. The best studies put HSCT therapy in the context of the many treatments that patients with high-risk leukemia receive, and attempt to define specific therapies that are associated with late effects. A recent example is found in a study by Goldsby et al. 4 , which showed that late neurological effects in ALL patients were associated with several factors including relapse, but not with HSCT. Patients and parents will make better choices when informed about the late effects risk that they already have, and the increase in risk they will have after HSCT compared with the increase they will have if chemotherapy is chosen.
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A second issue of concern to Dr Pinkel is the possible bias in studies that compare outcomes of chemotherapy or HSCT for various subsets of childhood leukemia. We all struggle with the fact that well-designed randomized controlled trials of HSCT vs chemotherapy have not been conducted successfully. However, this does not mean that nothing can be concluded from the comparative studies that have been conducted. Dr Pinkel states that in such studies 'many risks for treatment failure are unaccounted for such as socio-economic and insurance status, ethnicity, geographic residence and venue of patient care. Children receiving allogeneic HCT are usually treated in larger well-staffed centers with more abundant resources. ' We agree that many of these issues could affect the assessment of comparative studies of chemotherapy vs transplant. We are not familiar with the evidence supporting Dr Pinkel's assertion that smaller centers disproportionately use chemotherapy compared with larger centers, as the use of HSCT is generally based on the assumptions and experience of the treating physician, and many larger centers prefer chemotherapy approaches, whereas many smaller centers refer patients to other sites for HSCT, particularly after relapse has occurred. We welcome the study of this question, along with the other factors mentioned. Improvements in cord blood transplantation over the last several years has largely addressed issues of access to unrelated HSCT, allowing Black, Hispanic and Asian/Pacific populations formerly unable to find adequate HLA matches the ability to undergo safer, more efficacious procedures (490% of children from all ethnic backgrounds now have acceptable cord blood matches in the registry if other stem cell sources are not available). Survival outcomes of recipients of appropriately matched and dosed cords are now equivalent to recipients of matched unrelated donors. 5 Along similar lines, one would also need to consider legitimate concerns that a decision to refer a patient for HSCT may reflect the physician's assessment of the patient as being higher risk, compared with those receiving chemotherapy. Clinicians may prefer chemotherapy treatment in patients who respond rapidly, whereas those same clinicians may refer their more worrisome patients for HSCT (that is, those with poor response or a history of complications with or inability to tolerate important chemotherapy agents such as vincristine, asparaginase and so on). As opposed to Dr Pinkel's assertion that nonmeasured biases are working in favor of better outcomes for HSCT, it is possible that biases in comparative trials may favor chemotherapy. With this in mind, trials should be designed to gather sufficient information to minimize bias. To illustrate this point, we will review two trials discussed by Dr Pinkel that illustrate the pitfalls of comparative studies, and then contrast them with two comparative trials that incorporate design elements that greatly improve the validity of their conclusions.
The first trial to mention is the UKALLR1 study. 6 The study design intended treatment of higher-risk patients with matched sibling allogeneic HSCT, whereas those not having an available sibling donor were to be randomized between autologous HSCT and chemotherapy. Although the design seemed reasonable, emerging data during the trial period showed no advantage of autologous transplantation over chemotherapy, and success with unrelated donor HSCT led some clinicians to pull their highest-risk patients off the trial for this therapy. This led to an astonishing outcome: only 9% of eligible patients were randomized as intended. By modern standards, this trial would have closed and comparative analysis deemed impossible. Instead, a comparison of related donor HSCT vs unrelated donor HSCT vs autologous HSCT vs chemotherapy was attempted, in spite of the admission by the authors that the groups were not comparable by risk factor profile. A 'statistical correction' for risk was included, but when the choice of unrelated HSCT is heavily weighted toward increased risk, and other therapies are applied by clinician preference, post hoc statistical correction of biased assignment to consolidation therapies is impossible. The lesson from the UKALLR1 trial is that a fair comparison of chemotherapy with HSCT must be either planned and carried out properly, or based on risk. Mixing groups of different risk may cancel an effect, because high-risk patients, who may benefit more from HSCT, can be diluted by intermediate risk patients, in whom transplant outcomes could either be similar to chemotherapy or worse.
A second comparison, put forward by Dr Pinkel as evidence that HSCT outcomes are not different compared with chemotherapy for relapsed ALL, instead shows that conclusions cannot be drawn when critical data are not available. The paper described the survival outcomes of patients treated initially on the CCG-1952 standard-risk ALL study who relapsed. 7 Although the global picture of how patients do after relapse was valuable, an opportunity to compare HSCT with chemotherapy was lost because critical details about the HSCT procedures were not available, and risk-based analysis was not carried out. Of the 89 patients undergoing HSCT, the stem cell source was unknown in 39 patients (44%). Among the cord blood, unrelated donor and sibling stem cell sources that were known, degree of HLA match was not available. The type of preparative regimen and whether the patient was in remission at the time of transplant was unknown. There are major differences in outcome in ALL patients with total body irradiation (TBI) vs non-TBI regimens, partially mismatched vs matched related and unrelated HSCT, and most importantly, patients who go to transplant in CR vs active disease. The authors of this paper excluded from analysis those in the chemotherapy cohort who had a second relapse or who died before day 130 (median time to transplant), but did not exclude those in the transplant group who had a second relapse and still went to transplant or who went to transplant with active disease. The global picture of what happens to patients after relapse presented in this publication is useful, but the analysis of HSCT vs chemotherapy outcomes is not helpful and does not inform treatment decisions. Furthermore, outcomes of primary therapy for standard-risk ALL patients have improved significantly over those attained in this study, hence the population of standardrisk ALL patients that relapse now is likely quite different compared with the CCG 1952 relapse population. Thus, a patient with standard-risk ALL that relapses today who is eligible for a TBI-based procedure and has a matched donor gains no insight into whether they should choose chemotherapy over HSCT based on this paper.
Two other studies illustrate approaches that allow more informative comparison of HSCT with chemotherapy. Eapen et al.
8 compared well-established risk groups, early (o36 months from diagnosis) and late (X36 months from diagnosis) bone marrow relapse with transplantation from matched siblings vs chemotherapy given on high-quality, era-appropriate chemotherapy from three Pediatric Oncology Group relapse trials. All patients achieved a second remission, median time to transplant was corrected for and transplant regimens were known. A significant difference in DFS was noted with TBIbased transplant vs chemotherapy approaches in early relapse, while outcomes were equivalent for late relapse. Dr Pinkel mentions this paper briefly, but dismisses it because of a lack of overall survival data. Overall survival data were included in this publication, and it was also highly statistically significant (see Table 2 ). This study illustrates the necessity of only including patients who achieve remission, knowing the details of the transplant therapy they receive and comparing similar risk groups. A second example of a different, valid comparative study design is found in a report analyzing the outcomes of highrisk T-ALL in the Berlin-Frankfurt-Mü nster 90 and 95 trials. 9 The investigators appropriately did the following: (1) defined a high-risk population with poor chemotherapy outcomes with current era approaches, (2) included only patients who achieved remission and timed outcomes from the time remission was achieved, (3) assigned an 'SCT' cohort based on the presence of a matched sibling donor and transplanted them with an effective regimen, (4) corrected the chemotherapy cohort for median time to transplant and (5) carried out an intent-to-treat analysis. The study showed a statistically significant improvement in disease free survival by intent-to-treat (Table 2) , with a more significant difference noted according to actual therapy received. Much about the outcomes of this study has changed. Better results are now obtained with chemotherapy for children with high-risk T-ALL, and HSCT indications have changed. However, the principles behind this study design and analysis are sound.
In summary, it is vital that investigators continuously evaluate the role of allogeneic HSCT in the treatment of children with leukemia as chemotherapy and HSCT treatment modalities evolve. Studies must include data that are necessary to assess HSCT appropriately: state of remission at transplant (minimal residual disease status if possible), stem cell source (with HLA matching and cell dose), preparative regimen and whether therapy to treat relapse after transplant was successful. Studies should compare risk groups that are similar, as HSCT may have different risk/benefit ratios with different risk groups, and lumping of groups of different risk to obtain statistical power may inadvertently hide an advantage in one of the risk groups. Analyses of specific transplant interventions should either start at the attainment of initial remission, or only include patients who achieve remission and maintain that remission to time of transplant. Inclusion of patients who fail to achieve remission (for whom both chemotherapy and HSCT are futile therapies) may prejudice outcomes against a smaller or an unbalanced cohort. Finally, studies of the late effects of HSCT should attempt to discern what HSCT adds to the late effects risk patients already have with the sometimes extensive, intense chemotherapy treatment they have received before transplant, and contrast that with additional risks added by chemotherapy approaches. This information can help families put survival statistics of HSCT or chemotherapy in context and aid them in making the best decision for their therapy. Table 2 Survival outcomes of two studies in which more informative comparative methodology was used Acute myeloid leukemia (AML) is a heterogeneous disease, and AML with normal karyotype (AML-NK) is categorized as an intermediate-risk group based on cytogenetic stratification. However, molecular analyses successfully identified biomarkers that further allowed dissecting clinically meaningful subgroups. In AML-NK, acquired mutations with prognostic relevance were identified for FLT3, CEBPA, and NPM1. 1 FLT3-internal tandem duplication (ITD) mutations were associated with short relapse-free and overall survival, whereas mutations in CEBPA or NPM1Fwithout concomitant FLT3-ITDFhad a more favorable outcome. 2 Here, we present gene expression profiles of 251 de novo AML-NK cases. In three centers, microarray analyses were performed to delineate robust expression signatures for molecular markers and to elucidate the disturbance of cellular growth, proliferation, and differentiation processes in this disease.
All samples were obtained from untreated AML patients at the time of diagnosis (Dresden, n ¼ 78; Munich, n ¼ 96; Ulm, n ¼ 77). Cells were collected from the purified fraction of mononuclear cells after Ficoll density centrifugation. Each laboratory performed its routine diagnostic algorithms, including the characterization of molecular markers NPM1, FLT3, and CEBPA, as reported earlier. [2] [3] [4] [5] [6] Only AML samples with a NK were included. For conventional chromosome banding analysis, the median number of analyzed metaphases was 20 per case. The study design adhered to the tenets of the Declaration of Helsinki and was approved by ethics committees of the participating institutions before its initiation.
In all, 251 high-quality whole-genome Affymetrix HG-U133 Plus 2.0 gene expression profiles were generated in the three centers (Supplementary Tables S1-S3 ). Microarray analyses were performed following a standardized assay workflow as reported earlier (Supplementary Figure S1) . 7, 8 To visualize gene expression patterns, we applied hierarchical clustering and principal component analyses (see Supplementary Information) . Gene expression data were analyzed using GeneMaths XT Version 2.1 (Applied Maths, St-Martens-Latem, Belgium) and Partek Genomics Suite Version 6.4 (Partek Inc., St Louis, MO, USA). Microarray raw data and clinical patient annotation were deposited online in the Gene Expression Omnibus database under the accession number GSE15434. First, we focused on nucleophosmin gene (NPM1) mutations, the most frequent genetic lesion described in de novo adult AML-NK to date. 9 Gene expression signatures for 138 NPM1-mutated cases were compared to profiles of 113 NPM1-unmutated cases and a strong differential gene expression pattern was observed (Figure 1a ). This signature also showed a substantial overlap to the predictive NPM1 mutation signatures as published by Alcalay et al., 10 and Verhaak et al.
11
Our analyses confirmed 16/20 10 and 17/18 11 common genes in comparison to the published sets ( Supplementary  Figures S2 and S3) . With respect to the robustness of the differential gene expression signatures in NPM1-mutated cases across the participating laboratories, a consensus signature of 301 unique probe sets that belonged to the top-500 signature of a single center could be verified in both other centers (Figures 1b and c) .
Supervised classification analyses by 10-fold cross-validation resulted in 495% prediction accuracy of NPM1 mutation status (Supplementary Table S5 ). The sensitivity was very high for the positive detection of NPM1-mutated cases (497%). By using a resampling approach (100 iterations) and splitting the complete data into training (n ¼ 170) and test (n ¼ 81) sets, the high prediction accuracy was confirmed (Supplementary Table S6 ). The most frequently selected candidates with higher expression in NPM1-mutated cases comprised : HOXA1, HOXA2, HOXA3,  HOXA4, HOXA5, HOXA6, HOXA7, HOXA9, HOXA10,  HOXB2, HOXB3, HOXB4, HOXB5, HOXB6, HOXB7, HOXB9 , MEIS1, and PBX3. Lower expression in NPM1-mutated cases was observed for ABCB1, BAALC, MN1, MLLT3, or SPARC. A Gene Set Enrichment Analysis considering Gene Ontology (GO) terms 12,13 revealed the following biological processes to
